Literature DB >> 11889333

Severe status asthmaticus: management with permissive hypercapnia and inhalation anesthesia.

Gökhan M Mutlu1, Phillip Factor, David E Schwartz, Jacob I Sznajder.   

Abstract

OBJECTIVE: To describe the difficulties that can be encountered during mechanical ventilation of severe status asthmaticus and to discuss the safety of permissive hypercapnia as a ventilatory strategy and the role and limitations of inhalation anesthesia in the treatment of refractory cases.
DESIGN: Case series and review of literature.
SETTING: Intensive care unit of a tertiary care hospital. PATIENTS: Two patients with severe status asthmaticus.
INTERVENTIONS: Administration of inhalational anesthetics.
MEASUREMENTS AND MAIN RESULTS: Both patients had respiratory failure secondary to status asthmaticus requiring mechanical ventilation and permissive hypercapnia. They also received inhalational anesthetics because of refractory bronchoconstriction. Levels of PaCO(2) in each case were among the highest and most prolonged elevations (>150 mm Hg for several hours) reported to date. In one case, life-threatening difficulties with ventilation were encountered related to the use of an anesthesia ventilator. Although they had complications related to the severity of their illnesses, both were treated to recovery.
CONCLUSIONS: Mechanical ventilation in severe status asthmaticus can be challenging. Permissive hypercapnia is a relatively safe strategy in the ventilatory management of asthma. High levels of hypercapnia and associated severe acidosis are well tolerated in the absence of contraindications (i.e., preexisting intracranial hypertension). Inhalation anesthesia may be useful in the treatment of refractory cases of asthma but should be used carefully because it may be hazardous owing to poor flow capabilities of most anesthesia ventilators.

Entities:  

Mesh:

Year:  2002        PMID: 11889333     DOI: 10.1097/00003246-200202000-00034

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  15 in total

1.  Refractory Status Asthmaticus: Treatment With Sevoflurane.

Authors:  Lynn M Keenan; Terri L Hoffman
Journal:  Fed Pract       Date:  2019-10

2.  Peak pressures or plateau pressures in acute asthma.

Authors:  Ritesh Agarwal; Alok Nath
Journal:  Intensive Care Med       Date:  2006-10-26       Impact factor: 17.440

3.  Alteration of the piglet diaphragm contractility in vivo and its recovery after acute hypercapnia.

Authors:  Samir Jaber; Boris Jung; Mustapha Sebbane; Michèle Ramonatxo; Xavier Capdevila; Jacques Mercier; Jean-Jacques Eledjam; Stefan Matecki
Journal:  Anesthesiology       Date:  2008-04       Impact factor: 7.892

4.  Management of acute asthma in adults in the emergency department: assisted ventilation.

Authors:  Rick Hodder; M Diane Lougheed; J Mark FitzGerald; Brian H Rowe; Alan G Kaplan; R Andrew McIvor
Journal:  CMAJ       Date:  2009-11-09       Impact factor: 8.262

Review 5.  The critically ill asthmatic--from ICU to discharge.

Authors:  Samuel Louie; Brian M Morrissey; Nicholas J Kenyon; Timothy E Albertson; Mark Avdalovic
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

Review 6.  Critical asthma syndrome in the ICU.

Authors:  Michael Schivo; Chinh Phan; Samuel Louie; Richart W Harper
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

7.  Treatment of life-threatening hypercapnia with isoflurane in an infant with status asthmaticus.

Authors:  Yoshiki Masuda; Hiroomi Tatsumi; Kyoko Goto; Hitoshi Imaizumi; Shin-ichiro Yoshida; Tomohiko Kimijima; Michiaki Yamakage
Journal:  J Anesth       Date:  2013-12-06       Impact factor: 2.078

8.  Protein kinase A-Iα regulates Na,K-ATPase endocytosis in alveolar epithelial cells exposed to high CO(2) concentrations.

Authors:  Emilia Lecuona; Haiying Sun; Jiwang Chen; Humberto E Trejo; Margaret A Baker; Jacob I Sznajder
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

9.  Acute severe asthma: new approaches to assessment and treatment.

Authors:  Spyros A Papiris; Effrosyni D Manali; Likurgos Kolilekas; Christina Triantafillidou; Iraklis Tsangaris
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis.

Authors:  István Vadász; Laura A Dada; Arturo Briva; Humberto E Trejo; Lynn C Welch; Jiwang Chen; Péter T Tóth; Emilia Lecuona; Lee A Witters; Paul T Schumacker; Navdeep S Chandel; Werner Seeger; Jacob I Sznajder
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.